Why Is Regentis Biomaterials Stock Rising On Wednesday?

Regentis Biomaterials Ltd. (AMEX:RGNT), a regenerative medicine company stock, is trading higher on Wednesday following the official withdrawal of its proposed public share offering and accelerating commercial plans for its lead medical product.

SEC Public Offering Withdrawal

Regentis Biomaterials filed an application with the Securities and Exchange Commission (SEC) to officially withdraw its Form F-1 registration statement, effective as of June 15. The company stated in the filing that it “has determined not to pursue the public offering to which the Registration Statement relates.”

The company had proposed a public offering of 3.33 million ordinary shares at an assumed price of $3 per share to raise roughly $10 million on June 1. The withdrawal eliminates the immediate potential for equity dilution associated with the proposed share issuance.

European Commercialization Momentum

Market movement follows operational updates regarding the company’s core regenerative product, GelrinC, which is an off-the-shelf hydrogel implant designed for knee cartilage repair. The product has already received CE Mark approval in Europe.

Strategic Timeline And Rollout

Management stated that it will initiate European surgeon training in the third quarter of 2026. This step solidifies the corporate timeline toward active commercial deployment and revenue readiness in European markets.

Critical Levels To Watch for RGNT Stock

From a longer-term chart perspective, RGNT is still trying to recover from a rough 12 months (down 18.67%), but the near-term trend has flipped aggressively higher as the stock pushes deeper into the upper half of its 52-week range ($1.23 to $15.50). The current premarket price around $6.79 also keeps it well above key trend gauges: about 178% above the 20-day SMA ($2.45), about 160% above the 50-day SMA ($2.62), and about 103% above the 100-day SMA ($3.35).

One caution flag is that the 20-day SMA is still below the 50-day SMA, a bearish alignment that often shows the market is still working off earlier weakness despite the recent surge.

• Key Resistance: $7.50
• Key Support: $6

RGNT Stock Price Activity: Regentis Biomaterials shares were up 11.16% at $6.87 on Wednesday, according to Benzinga Pro data.

Photo: Shutterstock